File photo (Endpoints News)

In a sting­ing set­back, Pfiz­er’s can­cer block­buster Ibrance flops in key ad­ju­vant set­ting

One of Pfiz­er’s top, long-run­ning R&D cat­a­lysts has gone up in smoke, and it took an $11 bil­lion bite of their mar­ket cap in the process.

The mon­i­tor­ing com­mit­tee de­ter­mined that Pfiz­er’s ad­ju­vant study us­ing Ibrance com­bined with stan­dard en­docrine ther­a­py in an ad­ju­vant set­ting for ear­ly-stage breast can­cer has of­fi­cial­ly failed to make the cut. The com­bo failed to beat the stan­dard alone, trip­ping over the fu­til­i­ty analy­sis. And the Pfiz­er team will now wrap the study ear­ly af­ter pump­ing up hopes that their block­buster can­cer ther­a­py could find bil­lions more by prov­ing its ef­fi­ca­cy for dis­ease-free sur­vival in a ma­jor area — some­thing As­traZeneca just ac­com­plished with Tagris­so to great fan­fare.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.